Isavuconazole treatment of a patient with disseminated mucormycosis

J Clin Microbiol. 2014 Mar;52(3):1016-9. doi: 10.1128/JCM.03176-13. Epub 2014 Jan 8.

Abstract

We report a patient with relapsed acute myelogenous leukemia after allogeneic stem cell transplantation who developed disseminated mucormycosis due to Rhizomucor pusillus/R. miehei involving lung, brain, and skin. After failing posaconazole and being intolerant to amphotericin, he was treated effectively with isavuconazole for over 6 months despite ongoing treatment for relapsed leukemia.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / therapeutic use*
  • Brain / microbiology
  • Brain / pathology
  • Humans
  • Immunocompromised Host
  • Leukemia, Myeloid, Acute / complications
  • Leukemia, Myeloid, Acute / therapy
  • Lung / microbiology
  • Lung / pathology
  • Male
  • Middle Aged
  • Mucormycosis / diagnosis*
  • Mucormycosis / drug therapy*
  • Mucormycosis / microbiology
  • Nitriles / therapeutic use*
  • Pyridines / therapeutic use*
  • Rhizomucor / isolation & purification*
  • Skin / microbiology
  • Skin / pathology
  • Stem Cell Transplantation / adverse effects
  • Transplantation, Homologous / adverse effects
  • Treatment Outcome
  • Triazoles / therapeutic use*

Substances

  • Antifungal Agents
  • Nitriles
  • Pyridines
  • Triazoles
  • isavuconazole